[HTML][HTML] Tiotropium versus salmeterol for the prevention of exacerbations of COPD

…, MPMH Rutten-van Mölken, KM Beeh… - … England Journal of …, 2011 - Mass Medical Soc
Background Treatment guidelines recommend the use of inhaled long-acting bronchodilators
to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-…

Minimal clinically important differences in pharmacological trials

…, KM Beeh, KR Chapman, M Decramer… - American journal of …, 2014 - atsjournals.org
The concept of a minimal clinically important difference (MCID) is well established. Here, we
review the evidence base and methods used to define MCIDs as well as their strengths and …

Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4

KM Beeh, O Kornmann, R Buhl, SV Culpitt… - Chest, 2003 - Elsevier
Study objectives: Neutrophilic inflammation is a major feature of COPD. Several factors in
bronchial secretions have been identified as chemoattractants for neutrophils. The present …

[HTML][HTML] Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme

…, AM Kirsten, O Kornmann, KM Beeh… - … England Journal of …, 2015 - Mass Medical Soc
Background The most prevalent phenotype of asthma is characterized by eosinophil-dominated
inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of …

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

KM Beeh, D Singh, L Di Scala… - International journal of …, 2012 - Taylor & Francis
Kai M Beeh has received compensation for serving on advisory boards for Boehringer …
The institution where Kai M Beeh is currently employed has received compensations for design …

[HTML][HTML] Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial

KM Beeh, T Glaab, S Stowasser, H Schmidt… - Respiratory …, 2013 - Springer
Background Data examining the characteristics of patients with frequent exacerbations of
chronic obstructive pulmonary disease (COPD) and associated hospitalisations and mortality …

How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?

KM Beeh, PR Burgel, FME Franssen… - American journal of …, 2017 - atsjournals.org
Decreasing the frequency and severity of exacerbations is one of the main goals of treatment
for patients with chronic obstructive pulmonary disease. Several studies have documented …

The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease

KM Beeh, J Beier - Advances in therapy, 2010 - Springer
Bronchodilators are the cornerstone of symptomatic treatment for all chronic obstructive
pulmonary disease (COPD) severity stages when administered on a regular basis to prevent or …

Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial

…, C Vogelmeier, H Kögler, H Schmidt, KM Beeh… - Chest, 2013 - Elsevier
Background There is still a lack of data on the seasonality of exacerbations of COPD based
on large randomized studies using COPD exacerbations as primary end points. The …

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

H Watz, T Troosters, KM Beeh… - … Journal of Chronic …, 2017 - Taylor & Francis
Kai M Beeh’s institution has received compensation for organizing or participating in
advisory boards (from Almirall Hermal, Cytos, Chiesi, Boehringer Ingelheim, AstraZeneca, …